Evidence map›Paper›PMID 37847437›Full record

ReviewClinical and experimental nephrology2024

The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances.

Xinping Chen, Xuan Li, Kexin Zhang, Kexin Lian, Wenqiang Zhang, Yixin Song, Chengxia Kan, Jingwen Zhang, Fang Han, Xiaodong Sun and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical and experimental nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Xinping Chen *Department of Nephrology, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China.
Xuan Li *Department of Nephrology, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China.
Kexin ZhangDepartment of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, 2428 Yuhe Road, Weifang, 261031, China.
Kexin LianDepartment of Nephrology, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China.
Wenqiang ZhangDepartment of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, 2428 Yuhe Road, Weifang, 261031, China.
Yixin SongDepartment of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, 2428 Yuhe Road, Weifang, 261031, China.
Chengxia KanClinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China.
Jingwen ZhangClinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China.
Fang HanDepartment of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, 2428 Yuhe Road, Weifang, 261031, China.
Xiaodong SunClinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China. xiaodong.sun@wfmc.edu.cn.ORCID https://orcid.org/0000-0001-7775-2823
Zhentao GuoDepartment of Nephrology, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China. guozt@wfmc.edu.cn.ORCID http://orcid.org/0009-0002-5232-7913
Weifang Medical University · CN

Funding

National Natural Science Foundation of China 82170865Taishan Scholar Foundation of Shandong Province tsqn202211365
6 · The paper itself

Abstract

backgroundChronic kidney disease (CKD) poses a significant health risk in contemporary society. Current CKD treatments primarily involve renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor antagonists, albeit associated with hyperkalemia risks. A novel selective mineralocorticoid receptor antagonist, finerenone, offers a promising, safer alternative for CKD therapy. This review comprehensively assesses the role and efficacy of finerenone in CKD treatment by analyzing clinical and animal studies. Emerging evidence consistently supports finerenone's ability to effectively slow the progression of CKD. By targeting the mineralocorticoid receptor, finerenone not only mitigates renal damage but also exhibits a favorable safety profile, minimizing hyperkalemia concerns.

conclusionFinerenone emerges as a valuable addition to CKD therapy, demonstrating potential benefits in delaying CKD progression while minimizing side effects. Nevertheless, further clinical trials are necessary to provide a comprehensive understanding of its safety and efficacy.

Indexed as

Diabetes Mellitus, Type 2HyperkalemiaRenal Insufficiency, ChronicAnimalsMineralocorticoid Receptor AntagonistsNaphthyridinesfinerenoneMineralocorticoid Receptor AntagonistsNaphthyridinesChronic kidney diseaseFibrosisFinerenoneInflammationMineralocorticoid receptor

Identifiers

PMID37847437
OpenAlexW4387692642

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.